Status:

COMPLETED

Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Conditions:

Mood Disorders

Eligibility:

All Genders

7-11 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) versus placebo in treating children with temper outbursts and severe mood disorders.

Detailed Description

Depakote has been used to treat seizures in children for more than 20 years. The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) in treating children with tempe...

Eligibility Criteria

Inclusion

  • Meets criteria for Explosive Mood Disorder (EMD)
  • Explosive temper as evidenced by four or more outbursts of rage, property destruction, or fighting per month
  • Mood liability as evidenced by multiple, daily, distinct shifts from normal to irritable mood with withdrawn or boisterous behavior, occurring without a clear precipitant
  • History of an EMD for one year without treatment
  • EMD symptoms resulting in impairment in two or more of the following areas: school, the law, family, substance use, peers, or work
  • EMD symptoms do not occur only during substance toxicity or withdrawal
  • EMD symptoms are not confined to a single setting or context
  • Parent and child willing to consent to study
  • Inadequate response to an adequate trial (8 weeks) of psychotherapy and/or family therapy

Exclusion

  • Meets criteria for pervasive developmental disorder or childhood schizophrenia
  • Seizure or other neurologic disturbance
  • Pregnant
  • Moderate to severe mental retardation
  • Physical exam or laboratory results with significant abnormalities
  • Positive Hepatitis screen test
  • Liver dysfunction
  • Active suicidal or homicidal ideation
  • History of suicide attempts
  • History of barbiturate use
  • Unequivocal manic or hypomanic episode
  • Meets criteria for attention deficit hyperactivity disorder (ADHD) and has not failed a trial of psychostimulants for ADHD
  • Meets criteria for major depression in prepuberty
  • If female, unwilling to use an effective method of contraception for the duration of the study
  • Mitochondrial disease or family history of mitochondrial disease

Key Trial Info

Start Date :

September 1 2000

Trial Type :

INTERVENTIONAL

End Date :

August 1 2005

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00217932

Start Date

September 1 2000

End Date

August 1 2005

Last Update

January 12 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York State Psychiatric Institute

New York, New York, United States, 10032